Acutaas Chemicals: The Semiconductor Story That Isn't Driving the Stock

Acutaas Chemicals has become one of the most discussed names in Indian markets as the country's only domestic manufacturer of semiconductor photoresist chemicals. The narrative around the stock centers on its South Korean venture with Indichem Inc., a joint operation that will produce high-purity chemicals used in chip manufacturing. Analysts point to India's first foothold in the Korean semiconductor supply chain. Retail investors talk about AI demand and deglobalization of chip materials. The stock has gained more than 120 percent in the past year.

The problem with this story is that it describes a business that does not yet exist.

The semiconductor chemical segment contributed 15.7 crore rupees to Acutaas's 1,339 crore rupees in revenue last fiscal year. That is 1.2 percent. The Indichem plant in South Korea is still under construction. Management expects it to begin generating revenue in fiscal year 2028, and requires three to four years to reach full capacity. Even at the peak that management envisions, the facility will generate revenue equivalent to the investment — roughly 200 crore rupees — at margins comparable to the specialty chemicals segment, around 24 percent EBITDA. That is a respectable business. It is not what has priced a 25,500 crore rupees market capitalization.

The stock is being valued as a semiconductor play. The evidence shows it is a pharmaceutical CDMO company with a semiconductor option.

The distinction matters because these are two different businesses with different margin profiles, different growth trajectories, and different risks. The semiconductor story justifies the valuation multiple only if it materializes on schedule, at scale, and at margins that sustain the multiple. The pharmaceutical business is what is actually producing the earnings.

The pharma business doing the heavy lifting

Acutaas's core operation is the manufacture of pharmaceutical intermediates and contract development and manufacturing for innovator drug companies. This segment generated 1,174 crore rupees in fiscal year 2026, accounting for 87 percent of total revenue. It grew from 568 crore rupees in fiscal year 2024, nearly doubling in two years. The pharma segment operates at approximately 36 percent EBITDA margin, compared to roughly 24 percent for specialty chemicals and the expected 24 percent for the Indichem operation.

The company's consolidated financials reflect this mix. Revenue nearly doubled from 718 crore rupees in fiscal year 2024 to 1,339 crore rupees in fiscal year 2026. EBITDA margins expanded from 17.9 percent to 35.9 percent. Profit after tax grew from 80.8 crore rupees to 356.4 crore rupees. Return on capital employed jumped from 11.4 percent to 39.3 percent. These are not semiconductor numbers. They are the result of shifting from commoditized bulk chemicals to high-margin contract manufacturing for branded pharmaceutical companies.

The single largest growth driver is a 10-year supply agreement for an intermediate used in darolutamide, a prostate cancer drug marketed as Nubeqa. The contract is through Fermion Oy, a subsidiary of Orion Pharma, with Bayer as the end customer. Nubeqa has demonstrated strong efficacy and a favorable safety profile relative to competing treatments, and management expects end-customer demand to grow by 50 percent by 2026. Four additional CDMO products are awaiting regulatory approval and expected to begin contributing revenue in the second half of fiscal year 2027, with each potentially generating 50 to 100 crore rupees annually at peak. Management targets 1,000 crore rupees in CDMO-specific revenue by fiscal year 2028.

The pharma CDMO business explains the revenue growth, the margin expansion, and the capital returns. It is also what investors are actually buying at the current price.

The Indichem plant: timeline and economics

The semiconductor venture deserves examination on its own terms rather than as a dismissal. The deal was structured as follows: Acutaas Advance Material Limited, a wholly owned subsidiary of Acutaas Chemicals, acquired a 75 percent controlling stake in Indichem Inc., a joint venture originally formed in June 2025 between Acutaas and South Korea's J & Materials Co. Ltd. The remaining 25 percent is held by J & Materials.

The plant is located in the Namgongju General Industrial Complex in Gongju, South Chungcheong Province. The site covers 16,500 square meters. The investment is approximately 30 billion won, equivalent to roughly 200 crore rupees. The facility will produce advanced organic chemical materials used in photoresists, a critical component in the photolithography process that defines circuit patterns on silicon wafers.

The supply chain model is worth noting. Raw materials will be supplied by Acutaas from its Indian manufacturing facilities and processed at the Gongju facility. The stated objective is to replace the existing China-to-Japan supply chain model — where raw materials are sourced from China and processed in Japan — with a Korea-based production model. This positions Indichem to serve South Korean semiconductor manufacturers directly, reducing the supply chain risk that caused disruptions during the 2021 urea crisis.

Management's own timeline and margin expectations tell the full story. Construction is expected to finish by the end of the second quarter of fiscal year 2027. Revenue recognition is projected to begin in fiscal year 2028. The ramp-up to full capacity will take three to four years. The margin profile is expected to be 24 percent EBITDA, benchmarked against the specialty chemicals segment rather than the 36 percent pharma segment. Peak revenue is projected at approximately 200 crore rupees.

These numbers are internally consistent. They also show why the semiconductor business cannot carry the current valuation. At 200 crore rupees in peak revenue with 24 percent EBITDA margins, the business would generate roughly 48 crore rupees in annual EBITDA. Acutaas currently trades at a price-to-earnings multiple of approximately 70 times. Even applying the same multiple to the incremental earnings from Indichem, the standalone value of the semiconductor business at full ramp would represent a small fraction of the current 25,500 crore rupees market capitalization.

The semiconductor story has served as a powerful narrative catalyst. It has not, and cannot in the next two years, serve as the earnings foundation.

What the market is pricing

Acutaas reported 356.4 crore rupees in profit after tax for fiscal year 2026. At a 25,500 crore rupees market capitalization, the implied P/E multiple is approximately 70 times. This is above the company's own three-year historical median P/E of approximately 50 times and above the industry median of 63 times. Foreign institutional investors increased their stake to 21.6 percent in June 2026, up sequentially from 16.7 percent in December 2025. The institutional buying has been the primary force behind the multiple expansion.

The market appears to be pricing three things simultaneously: the pharma CDMO growth that is already flowing through to the income statement, the battery chemical business that has just begun commercial production with 2,000 tonnes per annum of capacity for each of two electrolyte additives, and the semiconductor photoresist operation that will not generate revenue until fiscal year 2028.

Management guides for 25 percent revenue growth in fiscal year 2027, which would push annual revenue toward 1,670 crore rupees. EBITDA margins are expected to stabilize near the 32 to 33 percent range, below the 35.9 percent achieved in fiscal year 2026. Management attributed the expected margin normalization to the growing revenue contribution from lower-margin battery chemicals and early-stage semiconductor operations. The Q1 fiscal year 2027 results confirm this dynamic — EBITDA margins reached 34.3 percent but management cautioned that the expansion was driven by the high-margin pharma mix and expected normalization as the new businesses ramp.

At 70 times earnings, the multiple is already pricing sustained double-digit growth for several years, flawless execution across three new business lines, and no competitive disruption in any segment. It is not pricing perfection. It is pricing certainty.

The global photoresist context

The broader market for semiconductor photoresist chemicals provides additional context for the Indichem opportunity. Global photoresist chemicals were valued at approximately 38 billion U.S. dollars in 2025, with projections to reach 63.8 billion dollars by 2034. The semiconductor-specific photoresist segment is smaller, valued at approximately 3.2 billion dollars in 2026 and projected to grow at roughly 11 percent annually through 2031.

The market is dominated by Japanese incumbents — JSR, Tokyo Ohka Kogyo, Shin-Etsu Chemical, and Fujifilm — which collectively control the majority of the advanced photoresist market. These companies have decades of customer qualification relationships with the world's largest semiconductor manufacturers. Photoresists are not commodities; they are highly engineered materials that require extensive qualification processes. A wafer fab will not switch suppliers without multi-year testing and validation.

Indichem enters this market as a new supplier with no established track record, targeting customers in a market where incumbents have deeply entrenched qualification relationships. The Korea-based location helps — proximity to Samsung, SK Hynix, and other major fabs shortens the feedback loop. The China-substitution narrative helps — Seoul has a strong policy incentive to reduce dependence on Chinese raw materials. But customer qualification in photoresists is measured in years, not quarters.

This does not mean Indichem will fail. It means the path from "plant under construction" to "material revenue contribution" will be longer and more uncertain than the current market pricing implies.

The condition to watch

The investment case for Acutaas resolves around a single question: is this stock being valued for what it is or for what it might become?

The pharma CDMO business is real, growing, and high-margin. It generated 1,174 crore rupees in revenue last year and is the engine behind every headline profitability metric. If this business sustains its trajectory, delivering management's target of 1,000 crore rupees in CDMO revenue by fiscal year 2028 while maintaining margins in the mid-30 percent range, the core earnings story supports a meaningful valuation — just not necessarily one at 70 times earnings without additional catalysts.

The semiconductor and battery businesses are optionality. They are genuine optionality, not vaporware. Acutaas has committed real capital, secured regulatory approvals in two jurisdictions, and is building a facility in a strategically important location. But optionality is not earnings, and optionality priced at 70 times current earnings requires it to materialize quickly and at scale.

The key issue is not whether Acutaas will eventually generate semiconductor revenue. The more important question is whether the market will continue to accept a multiple that assumes those earnings arrive on schedule, at expected margins, and without customer qualification delays. The pharma CDMO business determines whether the stock earns its current valuation. The semiconductor venture determines whether it can justify an expansion beyond it.